HIV type 1 subtype C gag and nef diversity in southern Africa
HIV type 1 subtype C gag and nef diversity in southern Africa
复制标题
DOI：
10.1089/aid.2006.0232
复制
发表时间：
2007-03-01
影响因子：
1.5
通讯作者：
Williamson, Carolyn
中科院分区：
文献类型：
--
作者：
Bredell, Helba;Martin, Darren P.;Williamson, Carolyn
几种HIV-1亚型C特异性gag和/或nef疫苗目前正在南部非洲进行临床试验。在这里，我们提供了在马拉维，赞比亚，津巴布韦和南非采样的64个gag和45个nef基因的序列，并评估了这些疫苗将面临的南部非洲HIV-1多样性的程度。而合理的系统发育证据存在的地理聚类亚型C gag和nef序列来自世界其他地区，有类似的人口创始人在南部非洲流行病的影响的证据很少。C亚型多样性的整个宽度在南部非洲的基因中表现出来，这表明生产地区或国家特异性的C亚型疫苗可能没有优势。然而，我们并没有在南部非洲的基因中发现很多亚型间重组的证据，这意味着由于亚型间重组体的出现而导致疫苗失败的可能性可能很低。
Several HIV-1 subtype C-specific gag- and/or nef-based vaccines are currently intended for clinical trial in southern Africa. Here we provide sequences of 64 gag and 45 nef genes sampled in Malawi, Zambia, Zimbabwe, and South Africa and assess the degree of southern African HIV-1 diversity that will confront these vaccines. Whereas reasonable phylogenetic evidence exists for geographical clustering of subtype C gag and nef sequences from various other parts of the world, there is little evidence of similar population founder effects in the southern African epidemic. The entire breadth of subtype C diversity is represented in the southern African genes suggesting there may be no advantage in producing region-or country-specific subtype C vaccines. We do not, however, find much evidence of intersubtype recombination in the Southern African genes, implying that the likelihood of vaccine failure due to the emergence of intersubtype recombinants is probably low.